Anand Mahadevan, MBBS

Anand Mahadevan practices at NYU Langone Perlmutter Cancer Center - 34th St in New York, New York.

Anand Mahadevan's NPI, 1891777389, was assigned on November 18, 2005. Anand Mahadevan graduated from Madras Medical College in 1988. Anand Mahadevan holds Pennsylvania license MD459457.

Anand Mahadevan's primary practice is NYU Langone Perlmutter Cancer Center - 34th St, at 14 Wall St, New York, NY 10005 in New York County. The practice phone is (212) 263-1481.

Anand Mahadevan's primary practice is NYU Langone Perlmutter Cancer Center - 34th St in New York, New York. Anand Mahadevan is also affiliated with Tisch Hospital. The medical group on file is NYU Langone Orthopedic Surgery Associates. Dmand AI also links Anand Mahadevan to 2 more hospitals and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Anand Mahadevan practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Anand Mahadevan's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Anand Mahadevan is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Anand Mahadevan's licenses on file in 5 states: Pennsylvania, Arkansas, Massachusetts, New York and Iowa.

Dmand AI lists bone cancer radiation, breast cancer radiation, cancer radiation-upper GI, colorectal cancer radiation, head & neck cancer radiation, lymphoma radiation, pancreatic cancer radiation and prostate cancer radiation among the conditions Anand Mahadevan treats.

CMS data shows 765 Medicare services from Anand Mahadevan across 11 procedure codes in 2024, for 111 Medicare patients. Medicare paid $75,212 for them.

CMS counts 111 Medicare patients who saw Anand Mahadevan in 2024. The largest group is 75 to 84, with 45 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 31% are also on Medicaid. Their average risk score is 2.72, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Anand Mahadevan's median patient age at 69, with 45% women.

In 2024, Anand Mahadevan wrote 20 Medicare Part D claims for 13 patients. 90% of them were for generic drugs. CMS names the drug for 14 of them, across 1 drug with 11 or more claims each, at $149 in total drug cost. In 2019, CMS named 11 claims across 1 drug.

Anand Mahadevan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Anand Mahadevan as offering telehealth.

Dmand AI links 60 papers to Anand Mahadevan, published from 2006 to 2024. 2015 was the busiest year, with 8. The most frequent topics are Radiosurgery, Brain Neoplasms and Radiotherapy Dosage. Anand Mahadevan has published most often in Int J Radiat Oncol Biol Phys. Anand Mahadevan's most frequent co-authors are Anand Raj Mahadevan, MD, Ekkehard Matthias Kasper, MD and Scott Richard Floyd, MD, PhD.

Dmand AI links Anand Mahadevan to 4 clinical trials, 2 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Glioblastoma, Astrocytoma and Neoplasm Metastasis. Beth Israel Deaconess Medical Center sponsors the most, 3.

CMS Open Payments shows 53 general payments to Anand Mahadevan from 14 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 51% of the total. Accuray Incorporated paid the most, $22,727.

Anand Mahadevan graduated from Madras Medical College in 1988.

Anand Mahadevan is in network with 17 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.